Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.

Department of Haematology, University College London Cancer Institute, London, United Kingdom.
New England Journal of Medicine (Impact Factor: 54.42). 12/2011; 365(25):2357-65. DOI: 10.1056/NEJMoa1108046
Source: PubMed

ABSTRACT Hemophilia B, an X-linked disorder, is ideally suited for gene therapy. We investigated the use of a new gene therapy in patients with the disorder.
We infused a single dose of a serotype-8-pseudotyped, self-complementary adenovirus-associated virus (AAV) vector expressing a codon-optimized human factor IX (FIX) transgene (scAAV2/8-LP1-hFIXco) in a peripheral vein in six patients with severe hemophilia B (FIX activity, <1% of normal values). Study participants were enrolled sequentially in one of three cohorts (given a high, intermediate, or low dose of vector), with two participants in each group. Vector was administered without immunosuppressive therapy, and participants were followed for 6 to 16 months.
AAV-mediated expression of FIX at 2 to 11% of normal levels was observed in all participants. Four of the six discontinued FIX prophylaxis and remained free of spontaneous hemorrhage; in the other two, the interval between prophylactic injections was increased. Of the two participants who received the high dose of vector, one had a transient, asymptomatic elevation of serum aminotransferase levels, which was associated with the detection of AAV8-capsid-specific T cells in the peripheral blood; the other had a slight increase in liver-enzyme levels, the cause of which was less clear. Each of these two participants received a short course of glucocorticoid therapy, which rapidly normalized aminotransferase levels and maintained FIX levels in the range of 3 to 11% of normal values.
Peripheral-vein infusion of scAAV2/8-LP1-hFIXco resulted in FIX transgene expression at levels sufficient to improve the bleeding phenotype, with few side effects. Although immune-mediated clearance of AAV-transduced hepatocytes remains a concern, this process may be controlled with a short course of glucocorticoids without loss of transgene expression. (Funded by the Medical Research Council and others; number, NCT00979238.).

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cochlear implants have provided hearing to hundreds of thousands of profoundly deaf people around the world. Recently, the eligibility criteria for cochlear implantation have been relaxed to include individuals who have some useful residual hearing. These recipients receive inputs from both electric and acoustic stimulation (EAS). Implant recipients who can combine these hearing modalities demonstrate pronounced benefit in speech perception, listening in background noise, and music appreciation over implant recipients that rely on electrical stimulation alone. The mechanisms bestowing this benefit are unknown, but it is likely that interaction of the electric and acoustic signals in the auditory pathway plays a role. Protection of residual hearing both during and following cochlear implantation is critical for EAS. A number of surgical refinements have been implemented to protect residual hearing, and the development of hearing-protective drug and gene therapies is promising for EAS recipients.This review outlines the current field of EAS, with a focus on interactions that are observed between these modalities in animal models. It also outlines current trends in EAS surgery and gives an overview of the drug and gene therapies that are clinically translatable and may one day provide protection of residual hearing for cochlear implant recipients.
    BioMed Research International 01/2014; 2014(Article ID 350504):17 pages. · 2.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: According to IARC a figures "rare and less common" cancers comprise more than a third of all cancer diagnoses as a group. However, advances in molecular biology have resulted in novel ways to classify cancers based upon genetic alterations and not just anatomical location, and this revised classification is at the heart of any move toward more personalised healthcare. It is now increasingly accepted that cancer should be thought of as many hundreds of more rare subtypes, each of which will have specific therapeutic options. We have selected colorectal carcinoma to illustrate the concept that each cancer is "rare", and demonstrate why this is important for delivering on the concept of Predictive, Preventive and Personalised Medicine (PPPM) for cancer in terms of prediction of who will get the disease, how it will behave and how to prevent it.
    Rare diseases: Integrative PPPM approach as the medicine of the future, Edited by Ozguc, 01/2015: pages 109-130; Springer., ISBN: 2211-3495
  • [Show abstract] [Hide abstract]
    ABSTRACT: Viral envelope proteins can enhance cellular secretion of non-enveloped virus.•Enhanced secretion of rAAV2 by VSVG was via exosome-mediated pathway.•Secreted rAAV2 particles were susceptible to AAV neutralizing antibodies.
    Biochemical Engineering Journal 01/2015; 93. · 2.37 Impact Factor


Available from
Jun 1, 2014